July 15, 2026 – South Carolina Attorney General Alan Wilson has joined a coalition of 48 states and territories in a $29.6 million settlement with generic drug manufacturer Glenmark over allegations the company conspired to artificially inflate prices, reduce competition, and restrain trade on numerous generic prescription drugs.
South Carolina’s share of the settlement is $118,890.
The Glenmark settlement follows previous settlements with Lannett, Bausch, Apotex, and Heritage totaling $66.95 million, bringing the combined total to more than $96 million. The states are preparing for the first trial in the broader litigation, anticipated to be held in Hartford, Connecticut in late 2026.
“These complex cases reveal one thing: these companies and individuals conspired to raise prices on generic drugs that millions of Americans rely on,” Wilson said. “Our office will continue to work to protect our citizens and hold those who break the law accountable.”
The first complaint named Heritage Pharmaceuticals and 17 other corporate defendants, two individual defendants, and 15 generic drugs. Two former Heritage executives, Jeffery Glazer and Jason Malek, have since entered into settlement agreements and are cooperating with investigators.
A second complaint was filed in 2019 against Teva Pharmaceuticals and 21 of the nation’s largest generic drug manufacturers, naming 16 individual senior executive defendants.
The third complaint, which is set to be tried first, focuses on 80 topical generic drugs accounting for billions of dollars in U.S. sales. It names 26 corporate defendants and 10 individual defendants. Seven additional pharmaceutical executives are cooperating to support the states’ claims.
The cases stem from a series of investigations built on cooperating witnesses, a document database of more than 20 million records, and a phone records database containing millions of call detail records and contact information for more than 600 sales and pricing individuals in the generics industry.
Prosecutors allege that competing industry executives coordinated illegal agreements through industry dinners, lunches, cocktail parties, golf outings, phone calls, emails, and text messages. Among the evidence obtained is a two-volume notebook containing contemporaneous notes from one cooperating witness memorializing discussions with competitors and internal company meetings over several years.
Consumers who purchased a generic prescription drug manufactured by Glenmark, Lannett, Bausch, Apotex, or Heritage between May 2009 and December 2019 may be eligible for compensation.
By Live 5 Web Staff
Read More Here